Amberen Perimenopause
Natural health product licensed in Canada
- Other names
- Amberen Perimenopause-Capsule purple, Amberen Perimenopause-Capsule white
- Licence holder
- Alliance Pharma Inc.
- NPN or DIN-HM
- 80124532
- Status
- Active licence
- Licence date
- 19 May 2023
- Revision date
- Not provided
- Form
- Kit
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Sodium | 46 mg | Not calculated |
| Acide L-glutamique | 31.44 mg | Not calculated |
| Acide aminoacétique Source : Glycine | 32 mg | Not calculated |
| Acide butanedioïque, Sel d'ammonium (1:2) Source : Succinate d'ammonium | 200 mg | Not calculated |
| Calcium Source : Disuccinate de Calcium Dihydraté | 11.885 mg | Not calculated |
| Zinc Source : Difumarate de Zinc Monohydraté | 1.66 mg | Not calculated |
| Magnésium Source : Disuccinate de Magnésium Tétrahydraté | 1.47 mg | Not calculated |
| Thiamine Source : Mononitrate de thiamine | 1.5 mg | Not calculated |
| Riboflavine Source : Riboflavine | 1.8 mg | Not calculated |
| Folate Source : Acide folique | 200 microgram | Not calculated |
Non-medicinal ingredients
Rouge FD&C N° 40, Stéarate de magnésium, Eau purifiée, Gélatine, Bleu FD&C n° 1, Farine de riz blanc, Rouge FD&C No. 3, Dioxyde de silicium, Dioxyde de titane, farine de riz
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Population not specified | minimum: 35 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps in the relief of perimenopausal symptoms including hot flashes, night sweats, occasional sleeplessness, irritability, moodiness and mild anxiety. Hels to reduce headaches, fatigue and low energy, muscle and joint aches associated with perimenopause.. Helps to support/promote healthy estrogen metabolism/balance. Source of antioxidants. Helps in energy production. Supports energy production.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80124532
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.